Leiomyosarcoma Drug Market Trends, Size, Competitive Analysis and Forecast 2022-2028
The global leiomyosarcoma drug market is expected to grow at a significant CAGR during the forecast period (2022-2028). Leiomyosarcoma is rare cancer that starts in the smooth muscle tissue of the body. Smooth muscle tissue can be found throughout the body, including the digestive system, urinary system, blood arteries, and uterus. The most common site of leiomyosarcoma is the abdomen or uterus. It begins as a proliferation of aberrant cells that quickly spreads to infect and destroy normal body tissue. Leiomyosarcoma signs and symptoms vary depending on where cancer begins. Pain, weight loss, and a developing lump or swelling that may be felt through the skin are all possible symptoms. Soft tissue sarcoma is a large category of tumors that arise in the tissues that link, support, and surround other body structures. A leiomyosarcoma is a form of soft tissue sarcoma. The chemotherapeutic drugs Adriamycin (Doxorubicin) and ifosfamide are presently used to treat leiomyosarcoma. Some people benefit from them, however, not everyone.
To Request a Sample of our Report on Leiomyosarcoma Drug
Market: https://www.omrglobal.com/request-sample/leiomyosarcoma-drug-market
The increasing clinical trials
associated with the leiomyosarcoma drugs is contributing to the growth of the
market. As per the study conducted by Eli Lilly and MSK in 2016, Olaratumab is
a targeted antibody medication that binds to and inhibits the PDGF-alpha
receptor, which is present on the surface of cancer cells and in the tumor
microenvironment (the area surrounding the tumor). Leiomyosarcoma was the most
prevalent subtype seen in the study. In this ailment, the drug appeared to
function exceptionally well. It was also remarkable that effectively it worked
in people who had already tried other treatments. However, Eli Lilly, the
manufacturer of olaratumab (Lartruvo), announced the drug's withdrawal from the
market on April 25, 2019. This decision was made after the medicine failed to
enhance survival in persons with soft tissue sarcoma in a phase III clinical
trial. The business announced that it was launching a programme to ensure that
patients who have benefited from the medicine can continue to use it.
The market players are
contributing significantly to the growth of the market by the adoption of
various strategies including mergers & acquisitions, geographical
expansion, partnerships and collaborations, and new product launches, to stay
competitive in the market. For instance, the first new anticancer treatments
approved by the FDA in 2020 are for the treatment of two kinds of soft tissue
sarcoma. The FDA authorized avapritinib (Ayvakit) for the treatment of certain
patients with gastrointestinal stromal tumours (GIST) on January 9, 2020, and
tazemetostat (Tazverik) for the treatment of certain patients with epithelioid
sarcoma on January 23, 2020.
Market Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2021-2027
Segment Covered-
·
By Product Type
·
By End-User
Regions covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape: Eli, Lilly & Co.,
and Advenchen Laboratories, LLC, among others.
(Get 15% Discount on Buying this Report)
A
full Report of Leiomyosarcoma Drug Market is Available @ https://www.omrglobal.com/industry-reports/leiomyosarcoma-drug-market
Global Leiomyosarcoma Drug Market Report by Segment
By Product Type
• AL-3818
• BGB-290
• C-21
• Others
By End-User
• Hospital
• Clinic
• Others
Global Leiomyosarcoma Drug Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries
are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other research-based
services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment